Journal
JCO ONCOLOGY PRACTICE
Volume 17, Issue 10, Pages 607-+Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1200/OP.20.00701
Keywords
-
Categories
Funding
- National Cancer Institute of the National Institutes of Health [U10CA180888]
Ask authors/readers for more resources
Despite efforts to improve enrollment and diversity in clinical trials, less than 5% of cancer patients participate in trials, and COVID-19 has exacerbated existing barriers. Academic and community researchers have created a white paper with recommendations to enhance efficiency in trial activation and conduct, aiming to provide better access and care for cancer patients.
Despite efforts to enhance enrollment and the merger of national cooperative groups, < 5% of patients with cancer will enroll into a clinical trial. Additionally, clinical trials are affected by a lack of diversity inclusive of minority patients, rural residents, or low-income individuals. COVID-19 further exacerbated known barriers of reduced physician-patient interaction, physician availability, trial activation and enrollment, financial resources, and capacity for conducting research. Based on the cumulative insight of academic and community clinical researchers, we have created a white paper identifying existing challenges in clinical trial conduct and have provided specific recommendations of sustainable modifications to improve efficiency in the activation and conduct of clinical trials with an overarching goal of providing improved access and care to our patients with cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available